GRAIL, Inc.
GRAL Healthcare Diagnostics & Research
GRAIL, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $147.2 million, up 17.2% from fiscal 2024.
- Revenue
- +3.71%
- EPS
- +10.2%
- Free cash flow
- −24.9%
Quarter to September 2026, against a year earlier
Follow GRAL
Alert me
GRAIL, Inc. (GRAL) P/B ratio
As of 5 November 2026, GRAIL, Inc. (GRAL) trades at a P/B ratio of 2.4×. Over the past ten years it has ranged from 0.1× (June 2024) to 3.0× (October 2026); the current reading is higher than 96% of that period. That is below the Diagnostics & Research industry median of 3.4× and in line with the Healthcare sector median of 2.3×.
P/B ratio, daily
Embed this chart
Annual newest first
| Period | P/B ratio | Change |
|---|---|---|
| FY2025 | 1.2× | 436.40% |
| FY2024 | 0.2× | 95.61% |
| FY2023 | 0.1× | 0.00% |
| FY2022 | 0.1× | — |
Quarterly newest first
| Period | P/B ratio | Change |
|---|---|---|
| Sep 2026 | 2.7× | 130.78% |
| Jun 2026 | 1.2× | 37.83% |
| Mar 2026 | 0.8× | (31.17%) |
| Dec 2025 | 1.2× | 27.97% |
| 9 more quarters | Free account |
Against its own ten years
P/B ratio against peers
| Company | P/B ratio |
|---|---|
| VCYT Veracyte, Inc. compare | 1.4× |
| ICLR ICON PLC compare | 1.7× |
| GRAL GRAIL, Inc. | 2.4× |
| QGEN QIAGEN N.V. compare | 3.1× |
| RDNT RadNet, Inc. compare | 4.4× |
| SHC Sotera Health Company compare | 6.2× |
| CDNA CareDx, Inc. compare | 8.6× |
| BLLN BillionToOne, Inc. compare | 9.9× |
| ADPT Adaptive Biotechnologies Corporation compare | 23.5× |
| Diagnostics & Research industry median | 3.4× |
| Healthcare sector median | 2.3× |
| Market median | 1.7× |
What P/B ratio is
Price to Book Value tells an investor how much the market pays for a company’s shares relative to the accounting net worth that belongs to common shareholders.
Stock Price ÷ (Common Equity (Total) (latest quarter) ÷ Shares (Basic, Weighted) (latest quarter))
More on GRAL
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement